Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant ...

A global clinical trial involving The Hospital for Sick Children (SickKids) has found that mavacamten—a heart medication ...

Learn when hypertrophic cardiomyopathy becomes severe and how a cardiologist guides you through heart transplant evaluation ...

Silvy came from a Riverside shelter through the Mission Viejo Animal Services Center’s Mission for Home program. Her cheerful, easygoing nature was evident as soon as she arrived; she is content ...

As of Friday, March 27, Rocket Pharmaceuticals, Inc.’s RCKT share price has dipped by 10.66%, which has investors questioning if this is right time to buy.

Parent Project Muscular Dystrophy (PPMD), the leading U.S. non-profit driving Duchenne and Becker muscular dystrophy care, research, and advocacy efforts, and Secretome Therapeutics (Secretome) are ...

If you have been spending any time in the pet community, online or in person, you’ve likely heard people talking about the ...

Longeveron Inc. () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing ...

On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric ...

Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript March 17, 2026 Longeveron Inc. beats earnings expectations.

Recorded a one-time accrued severance cost in 2025 related to the departure of the former CEO. Acknowledged that the PDCM ...

Potential Priority Review Vouchers (PRVs) -- The HLHS program holds rare pediatric disease designation, making Longeveron eligible for a PRV if approved; PDCM program could also achieve PRV ...